240618 AUXESIS Kallelse till årsstämma
The shareholders of AUXESIS PHARMA HOLDING AB (publ) with corporate number 559195-6486 are hereby invited
to the annual general meeting on June 18, 2024 at 3 p.m at Ramberg Advokater at Jakobsbergsgatan 13 in Stockholm.
Fintegrity AB – Scenario One Pager valuation of the shares in AUXESIS PHARMA HOLDING AB (publ) prior to the launch of the company’s analgesic product ASA.P® is now available.
Auxesis Pharma Holding AB has been granted Small and Medium-sized Enterprise (SME) status as of January 23, 2024, by the European Medicines Agency (EMA). Obtaining SME status from EMA means that the company will have easier access to regulatory, financial, and administrative support from EMA throughout the development stages of its products.The SME status can be extended on an annual basis as soon as information regarding the company’s financial performance for the previous fiscal year has been reported to EMA.
15 december 2023
While manufacturing is still pending, shares worth several million kronor were donated to save ÖFK’s elite license.
Now, the company behind the gift has taken a step closer to a factory in Östersund by patenting its version of pain-relieving aspirin.
“The first product will be a wet wipe,” says Roar Adelsten, CEO of Auxesis Pharma AB.
Maria Lindholm
Östersunds-Posten
Roar Adelsten, CEO, AUXESIS PHARMA HOLDING AB
Photography: Therése Särnbäck
He and his partners were in Östersund during the last home match in the The Super First Division.
They didn’t have time to watch the match, but they were introduced to the audience before kick-off as financially saving angels.
In August, ÖFK announced that the club had received a donation in the form of 110,000 shares in the company AUXESIS PHARMA HOLDING AB (publ). The shares were estimated to be worth 6 million kronor. The club sold the majority of the shares, thus increasing the funds needed to rescue the economy, reportedly by 4.3 million kronor.
Since then, the company has had regular contact with the municipality. The plans are to establish production in Östersund.
However, to start manufacturing drugs, both patent approval and approval from
the Medical Products Agency are required. And now, Auxesis has registered the former.
“We have registered the active components,” says Roar Adelsten, CEO of the newly established company.
The idea is to stabilize pain-relieving aspirin, which is normally dissolved in the form of an effervescent tablet. Instead, Auxesis wants to develop a way to manufacture the pain-relieving medicine in products applied directly to the skin. Cream has been mentioned before, but the first product to be manufactured will be a wet wipe, according to Roar Adelsten.
“One can imagine burning oneself on nettles or during the Christmas season when taking trays out of the oven and getting burned.
We also consider minor burns like sunburns,” he says.
With the patent registration, the company is now looking for a Lego manufacturer who can produce the wet wipes on a small scale. Alternatively, they can be developed in the laboratories available to the company at the Karolinska Institute, according to Roar Adelsten.
The next step is to test them on people and apply for market approval from the Medical Products Agency.
“By New Year’s, we will decide whether to rent an existing space in Östersund or build a new one from scratch. We have looked at locations, and there are high requirements due to the manufacturing of a pharmaceutical product. Owning the space ourselves is, of course, an advantage, but it’s not decided yet,” says Roar Adelsten.
We are thrilled to announce that AUXESIS PHARMA HOLDING AB (publ) has successfully submitted the application for its very first patent featuring the ASA.P formulation. A big thank you to EIP-Patent Office for the outstanding work put into this process.
This milestone is a testament to our dedicated team and their hard work. We look forward to future successes and are grateful for the support we’ve received along the way.
Thanks again to everyone involved for making this journey possible and exciting!
AUXESIS PHARMA HOLDING AB (publ) continues its “journey” by visiting the Business Office in Östersund Municipality on Friday 2023-10-27.
In addition, Region Jämtland/Härjedalen participates. The purpose of the visit is to begin operational planning with the establishment of a production plant within Östersund municipality.
AUXESIS PHARMA HOLDING AB (publ) is now a settlement company and started with Euroclear as the securities institution. This is the last phase (according to IPO) on the road to get there. We are now in the process to choose which Corporate Finance group we will cooperate with to get listed on the Stock Exchange of choice.
AUXESIS PHARMA HOLDING AB (publ) is in the establishment phase of pharmaceutical manufacturing in Östersund, Sweden.
In September 2023 the company will submit an application for a patent to the Patent and Registration Office Sweden. When filed, the plans are directed towards Östersund.
– We want to build a factory up there. We will start planning the factory when the research team at Karolinska in Stockholm is done with their job. We also wish to support football and want to get to know the municipality where we will establish ourselves, says Roar Adelsten.
Protocol from The AUXESIS PHARMA HOLDING AB (publ) Annual General Meeting 2023 is now available for download in the Investor Hub.
AUXESIS PHARMA HOLDING (publ) Annual report /Årsredovisning and associated documents regarding the Annual Meeting is now available for download in the Investor Hub for investors.
+46 (0)8-771 43 00
Besöksadress:
Skeppargatan 26Postadress:
Copyright All rights reserved AUXESIS PHARMA HOLDING AB (publ) 2023
